Gut Artriti ve Tedavisi
Özet
Gut, eklem ve dokularda monosodyum ürat kristallerinin birikmesiyle ortaya çıkan, dünya genelinde yaygın bir inflamatuvar artrit türüdür. Temel risk faktörü olan hiperürisemi, pürin metabolizmasının son ürünü olan ürik asidin aşırı üretimi veya böbreklerden atılımının azalmasıyla gelişmektedir. Klinik seyri; asemptomatik hiperürisemi, akut gut artriti, interkritik evre ve tofüs oluşumu ile eklem hasarının gözlendiği kronik evre olmak üzere dört ana aşamadan oluşur. Akut ataklar, özellikle sabaha karşı birinci metatarsofalangeal eklemde (podogra) şiddetli ağrı, şişlik ve kızarıklıkla karakterize monoartrit şeklinde kendini gösterir. Tanıda altın standart, sinovyal sıvıda iğne şeklinde ve negatif çift kırıcılığa sahip ürat kristallerinin polarize ışık mikroskobunda gösterilmesidir. Tedavi yönetimi ise non-farmakolojik yaşam tarzı ve diyet değişikliklerinin yanı sıra, akut ataklarda inflamasyonu hızla baskılayan ilaçları (NSAİİ, kolşisin, steroidler) ve kronik dönemde serum ürik asit düzeyini düşürmeyi hedefleyen allopürinol veya febuksostat gibi uzun vadeli farmakolojik ajanları kapsamaktadır.
Gout is a highly prevalent inflammatory arthritis globally, marked by the pathological deposition of monosodium urate crystals within articular tissues and joints. Hyperuricemia serves as the primary risk factor, arising from either the elevated production of uric acid or its impaired renal excretion. The clinical spectrum unfolds through four distinct phases: asymptomatic hyperuricemia, acute gouty arthritis, the intercritical period, and chronic tophaceous gout characterized by structural joint damage. Acute attacks typically present as excruciating monoarthritis with swelling and erythema, predominantly affecting the first metatarsophalangeal joint. The diagnostic gold standard involves identifying needle-shaped, negatively birefringent urate crystals in synovial fluid using polarized light microscopy. Therapeutic strategies combine essential non-pharmacological dietary modifications with targeted medication; acute flares are managed using rapid-acting anti-inflammatory agents like NSAIDs, colchicine, or corticosteroids, while long-term management incorporates urate-lowering therapies such as allopurinol or febuxostat to achieve optimal serum targets.
Referanslar
McCarty DJ, Holander JL. Identification of urate crystals in gouty synovial fluid. Annals of Internal Medicine.1961;54:452-460. doi: 10.7326/0003-4819-54-3-452
Paul BJ, Anoopkumar K, Krishan V. Asymptomatic hyperuricemia: is it time to intervene? Clinical Rheumatology. 2017;36(12):2637-2644. doi: 10.1007/s10067-017-3851-y
Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388(10055):2039-2052. doi: 10.1016/S0140-6736(16)00346-9
Wilson L, Saseen JJ. Gouty Arthritis: A review of acute management and prevention. Pharmacotherapy. 2016;36(8):906-922. doi: 10.1002/phar.1788
WJ Taylor, J Fransen, TL Jansen, et al. Study for updated gout classification criteria: identification of features to classify gout. Arthritis Care Res (Hoboken). 2015;67(9):1304-1315 doi: 10.1002/acr.22585
Dalbeth N, Gosling AL., Gaffo A. Gout. Lancet. 2021;397(10287):1843-1855. doi: 10.1016/S0140-6736(21)00569-9
Sidari A, Hill E. Diagnosis and treatment of gout and pseudogout for everyday practice. Primary Care. 2018;45(2):213-236. doi: 10.1016/j.pop.2018.02.004
Smith E, Hoy D, Cross M et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study. Annals of Internal Medicine. 2014;73(8):1470-1476. doi: 10.1136/annrheumdis-2013-204647
Zhu y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheumatology. 2011;63(10):3136-3141. doi: 10.1002/art.30520
Dalbeth N, Pool B, Gamble GD et al. Cellular characterization of the gouty tophus:a quantitative analysis. Arthritis Rheumatology. 2010;62(5):1549-1556. doi: 10.1002/art.27356
DG Palmer, J Highton, PA Hessian. Development of the gout tophus. An hypothesis. American Journal of Clinical Pathology. 1989;91(2):190-195. doi: 10.1093/ajcp/91.2.190
N Dalbeth, B Clark, K Gregory, et al.Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography. Annals of the Rheumatic Disease. 2009;68(8):1290-1295. doi: 10.1136/ard.2008.094201
A Chhana, KE Callon, B Pool et al. Monosodium urate monohydrate crystals inhibit osteoblast viability and function: implications for development of bone erosion in gout. Annals of the Rheumatic Disease.2011;70(9):1684-1691. doi: 10.1136/ard.2010.144774
A Chhana, B Pool, KE Callon et al. Monosodium urate crystals reduce osteocyte viability and indirectly promote a shift in osteocyte function towards a proinflammatory and proresorptive state. Arthritis Research& Therapy. 2018;20(1):208. doi:10.1186/s13075-018-1704-y
Jalal DI. Hyperuricemia, the kidneys, and the spectrum of associated diseases: a narrative review. Current Medical Research and Opinion. 2016;32(11):1863-1869. doi: 10.1080/03007995.2016.1218840
Richette P, Doherty M, Pascual E et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Annals of the Rheumatic Diseases. 2020;79(1):31-38. doi: 10.1136/annrheumdis-2019-215315
Dalbeth N , Phipps-Green A , Frampton C et al. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. Annals of the Rheumatic Diseases. 2018;77:1048-1052. doi: 10.1136/annrheumdis-2017-212288
Campion EW , Glynn RJ , DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. The American Journal of Medicine. 1987;82:421-426. doi: 10.1016/0002-9343(87)90441-4
Sivera F , Andrès M , Falzon L et al. Diagnostic value of clinical, laboratory and imaging findings in patients with a clinical suspicion of gout: a systematic literature review. The Journal of Rheumatology. 2014;92:3–8. doi: 10.3899/jrheum.140456
Ogdie A , Taylor WJ , Neogi T et al. Performance of ultrasound in the diagnosis of gout in a multicenter study: comparison with monosodium urate monohydrate crystal analysis as the gold standard. Arthritis& Rheumatology. 2017;69:429–438. doi: 10.1002/art.39959
Ogdie A , Taylor WJ , Weatherall M et al . Imaging modalities for the classification of gout: systematic literature review and meta-analysis. Annals of the Rheumatic Diseases. 2015;74:1868–1874. doi: 10.1136/annrheumdis-2014-205431
Neogi T , Jansen TL , Dalbeth N et al. Gout classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Annals of the Rheumatic Diseases. 2015;2015:1789–1798. doi: 10.1136/annrheumdis-2015-208237
Choi HK, Atkinson K, Karlson EW et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. The New England Journal of Medicine. 2004;350(11):1093-1103. doi: 10.1056/NEJMoa035700
Khanna D, Fitzgerald JD, Khanna PP et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care& Research (Hoboken). 2012;64(10):1431-1446. doi: 10.1002/acr.21772
Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336(7639):309-312. doi: 10.1136/bmj.39449.819271.BE
Choi HK, Willett W, Curhan G. Fructose-rich beverages and risk of gout in women. JAMA. 2010;304(20):2270-2278. doi: 10.1001/jama.2010.1638
E Roddy, K Clarkson, M Blagojevic-Bucknall et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases. 2020;79(2): 276-284. doi:10.1136/annrheumdis-2019-216154
TH Rainer, CH Cheng, HJ Janssens et al. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial. Annals of Internal Medicine. 2016;167(7): 464-471. doi: 10.7326/M14-2070
CY Man, IT Cheung, PA Cameron et al. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Annals of Emergency Medicine. 2007;49(5): 670-677. doi:10.1016/j.annemergmed.2006.11.014
HJ Janssens, M Janssen, EH van de Lisdonk et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371(9627):1854-1860. doi: 10.1016/S0140-6736(08)60799-0
Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707
Yamanaka H, Tamaki S, Ide Y et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Annals of the Rheumatic Diseases. 2018;77(2):270-276. doi:10.1136/annrheumdis-2017-211574
Takahashi S, Moriwaki Y, Yamamoto T et al. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Annals of the Rheumatic Diseases. 2003;62(6):572-575. doi: 10.1136/ard.62.6.572
List JF, Woo V, Morales E et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009; 32(4): 650-657. doi: 10.2337/dc08-1863
Gutiérrez-Macías A, Lizarralde-Palacios E, Martínez-Odriozola P et al. Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia. BMJ. 2005; 331(7517): 623–624. doi: 10.1136/bmj.331.7517.623
Stamp LK, Chapman PT, Barclay ML, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Annals of the Rheumatic Diseases. 2017; 76(9): 1522–28. doi: 10.1136/annrheumdis-2016-210872
White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. The New England Journal of Medicine. 2018; 378(13): 1200–1210. doi: 10.1056/NEJMoa1710895
Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Annals of the Rheumatic Diseases. 2009; 68(6): 892–897. doi: 10.1136/ard.2008.091462
Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Annals of the Rheumatic Diseases. 2009;68(1):51–56. doi:10.1136/ard.2007.083071
